Select Page

Hepatitis cases rise dramatically in Tennessee
“KNOXVILLE, Tenn. (WVLT) – Hepatitis cases are up dramatically across the state in the past year, with certain types of the disease more than doubling. Health officials believe a big reason is drug use. Hepatitis B and C can be transmitted through sharing needles. Leaders from the Knox County Public Health Department said it’s not surprising Hepatitis cases are rising, considering the opioid epidemic. So far this year, there have been 281 new cases of Hepatitis C in the entire state. That’s compared to 131 at this time last year, which is a 115% increase. County data shows that 28 of those cases are in Knox County. Hepatitis B cases are 35% statewide too, but only six of those cases are in Knox County.”

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model- Rencofilstat
“EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced the publication of a new research study in mice, where Hepion’s lead drug candidate, rencofilstat, prevented the growth of liver tumors that occurred as a result of chronic infection with the human hepatitis C virus (“HCV”).”

Mitochondrial DNA copy number in Hepatitis C virus-related chronic liver disease: impact of direct-acting antiviral therapy
“Hepatitis C virus (HCV) infection can regulate the number and dynamics of mitochondria, and is associated with a prominent hepatic mitochondrial injury. Mitochondrial distress conveys oxidative damage which is implicated in liver disease progression. The present study was conducted to assess the change of mitochondrial DNA (mtDNA) copy number in patients with HCV-related chronic liver disease and the impact of direct-acting antiviral (DAA) therapy.”

Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review
“Background. Hepatitis C infection often leads to extrahepatic manifestations, including cryoglobulinemic vasculitis. This systematic review aimed to assess the efficacy and safety of rituximab in treating hepatitis C-associated cryoglobulinemic vasculitis.”

Missouri Telehealth Network wins international awards
“The Missouri Telehealth Network (MTN) won a Global ECHO Excellence Award at the MetaECHO Global Conference last month for its depth and breadth of programming, focus on outcomes and success in improving the lives of patients and providers. Global ECHO Excellence AwardMTN initiated Show-Me ECHO in 2014, which connects local providers with multidisciplinary teams of experts. For example, the Hepatitis C ECHO provides support for primary care physicians who have never treated the disease before, allowing patients to receive care in their own community. The ECHOs facilitate virtual learning opportunities on a variety of topics and enable collaboration on patient cases.”

Protect your liver: how to prevent, get tested for, and treat hepatitis B and C infection
“Over 41,000 adults in the United States will be diagnosed with primary liver cancer this year. That’s more than half the seats in Lincoln Financial Field. Chronic hepatitis B and C can both put you at much higher risk for developing liver cancer. In fact, more than 75,000 Philadelphians have had chronic hepatitis B or hepatitis C over the last ten years. That’s why we’re focusing on chronic hepatitis during this Liver Cancer Awareness Month.”